| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2020: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2019: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
The main objective of this study was to comprehensively analyze ADCC activity in HIV-infected specimens as a basic research for a novel therapeutic strategy aimed at cure of HIV latently infected cells.
As a result, we succeeded in constructing a system for measuring ADCC activity and obtained basic data on the relationship between clinical course and ADCC activity, as well as the relationship between ADCC activity and reservoir size.
In addition, we developed the "expansion of the anti-HIV antibody enhancer library" for the purpose of enhancing ADCC activity, and succeeded in finding several categories of "anti-HIV antibody enhancers" and pharmacophores that differ not only in their chemical structural framework but also in their binding regions to target Envs. These are expected to contribute to the development of new therapeutic methods.
|
